(DailyVantage.com) – The COVID-19 pandemic has ravaged the world for more than two years. Several companies — including Johnson & Johnson, Moderna and Pfizer — came out with vaccines they touted to be the answer to curbing the spread of infection. Surprisingly, or perhaps not, experts said the two-dose inoculation wasn’t enough to protect against the Delta or Omicron variants, so Pfizer and Moderna sought and received approval for a booster. Now, it seems one booster isn’t enough.
On Thursday, March 17, Moderna sought an emergency use authorization request from the FDA for a fourth dose of its vaccine. Unlike Pfizer, which also requested approval for a fourth dose, Moderna’s request is much broader. Pfizer, along with BioNTech, asked the FDA for an EAU for adults 65 and older, a more susceptible population. Moderna, however, asked for the EAU to apply to all adults.
Breaking News: Moderna asked the FDA to authorize a second booster of its coronavirus vaccine for all adults. The request is significantly broader than Pfizer’s, which was for adults 65 and older. https://t.co/mrpciZX3eF
— The New York Times (@nytimes) March 18, 2022
The broader appeal, according to Moderna, is so physicians and the CDC can “determine the appropriate use of an additional booster dose.” The immunocompromised have already been authorized to receive a second booster shot.
While the US has seen a steady decrease in the number of infections, experts are worried the BA.2 variant, dubbed as “stealth Omicron,” will soon make its way into the country and cause another wave of infections.
Copyright 2022, DailyVantage.com